Professor Manuel Guzmán
Professor Guzmán is a Full Professor of Biochemistry and Molecular Biology at Madrid’s Complutense University. His PhD and postdoctoral research focused on the regulation of liver and brain lipid metabolism. During the last 20 years he has been mostly involved in the study of how cannabinoids act in the body, with special emphasis on the molecular mechanisms of that action and on understanding how cannabinoids control cell generation and death. This work has allowed him to characterise new effects and signalling pathways evoked by cannabinoids, as well as putting forward new physiopathological implications derived from them.
Professor Guzman has published 136 articles and 7 patents and supervised 15 PhD theses. He was the Secretary of the Spanish Society for Biochemistry and Molecular Biology (SEBBM) from 2006 to 2010 and is the founder current President of the Spanish Society for Cannabinoids Research (SEIC). He is also an Academic Member of The Royal National Academy of Pharmacy (Spain) as well as a member of the Board of Directors of the International Association for Cannabinoid Medicines (IACM). Professor Guzman resides in Spain.
Professor Cristina Sánchez
Dr Sánchez is an Associate Professor of Biochemistry and Molecular Biology and Vice Dean of Research of the School of Biology at the Complutense University of Madrid. Her PhD and postdoctoral training were focused on lipid signalling, including that of cannabinoids in an oncology setting. The goal of her current research is to understand and exploit cannabinoids as potential antitumoral agents in breast cancer. More recently, she has also focused her attention on new cannabinoid receptors and their possible involvement in cannabinoid antitumoral action in breast cancer and other types of tumors. She has been Secretary of the Spanish Cannabinoid Research Society (2011-2015) and is one of the founders and Secretary of the Spanish Observatory on Medicinal Cannabis. Dr Sanchez resides in Spain.
Dr Noah Federman
Dr Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at University of California (Los Angeles), part of the UCLA Sarcoma Program and UCLA’s Jonsson Comprehensive Cancer Centre. He specialises in treating children, adolescents and young adults with these aggressive cancers. He runs a comprehensive and multidisciplinary program involving paediatric and medical oncologists, radiation oncologists, orthopaedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists.
Dr Federman also specialises in conducting clinical trials and leads an experienced clinical research team devoted to providing access to clinical trials for children with refractory, recurrent and metastatic bone and soft tissue cancers.
Dr Federman received a BA in English Literature and minor in neuroscience at Williams College, Massachusetts. He received a Medical Doctorate Degree from the Mount Sinai School of Medicine – New York University, New York and completed his residency and fellowship training in Pediatric Hematology/Oncology at the University of California, Los Angeles. He is now a full-time member of the faculty at UCLA.
As a member of the Scientific Advisory Board Dr Federman will be instrumental in shaping the rigorous scientific research and clinical trials that Zelda plans to fund as part of its strategy to become a leading biotechnology company in the emerging medical cannabis sector.
Dr David Casarett
Dr Casarett is a palliative care physician and health services researcher whose work focuses on improving systems of care for people with serious, life-threatening illnesses. He a Professor of Medicine at Duke University and the Chief of Palliative Care in Duke Health.
Dr Casarett is the author of more than 100 articles in journals including JAMA and The New England Journal of Medicine, and his writing has appeared in print and online in Salon, Esquire, Discover, Newsweek, the New York Times and Wired. He is a recipient of the Presidential Early Career Award for Scientists and Engineers, the highest honour given by the US government to researchers in the early stages of their careers.
Dr Casarett is the director of Cannabis Outcome (www.CannabisOutcomes.com), a research consulting group that provides cutting-edge methods expertise to help the cannabis industry understand their patients’ experience and outcomes. He resides in the USA.
Dr Dustin Sulak
Dustin Sulak is an integrative medicine practitioner and leader in the emerging field of cannabinoid medicine. His clinical practice focuses on treating refractory conditions in adults and children. He received his undergraduate degrees in nutrition science and biology from Indiana University, a doctorate of osteopathy from the Arizona College of Osteopathic Medicine and completed an internship at Maine-Dartmouth Family Medicine Residency.
Dr Sulak is the founder of two specialist clinics in the US that have treated over 18,000 patients with medical cannabis. Dr Sulak is also the founder of Tested Labs, a cannabis analytic laboratory, and healer.com, a medical cannabis education resource. He sits on the board of directors of the Society of Cannabis Clinicians and lectures internationally on the science and clinical applications of cannabis. As an expert and educator on medical cannabis in the US, Dr Sulak has contributed to the standard of care for the use of medical cannabis in a wide variety of conditions including epilepsy, autism, pain, spasticity, seizure disorders and PTSD.